# Shiyao Group

Chinese Drugmaker Wins FDA Green Light to Test Next‑Generation Obesity Peptide in the US

Shiyao Group has won FDA permission to begin US clinical trials of a long‑acting peptide that acts on both GLP‑1 and GIP receptors for weight management in people with obesity or overweight plus comorbidities. The clearance permits investigational trials but falls short of marketing approval; success would boost China’s ambitions to compete in the lucrative obesity‑drug market dominated by Western firms.